Nuclear softening expedites interstitial cell migration in fibrous networks and dense connective tissues – Science Advances

INTRODUCTION

After injury or tissue damage, cells must migrate to the wound site and deposit new tissue to restore function (1). While many tissues provide a permissive environment for such interstitial [three-dimensional (3D)] cell migration (i.e., skin), adult dense connective tissues (such as the knee meniscus, articular cartilage, and tendons) do not support this migratory behavior. Rather, the extracellular matrix (ECM) density and micromechanics increase markedly with tissue maturation (2, 3) and, as a consequence, act as a barrier for cells to reach the wound interface. It follows then that healing of these tissues in adults is poor (4, 5) and that wound interfaces remain susceptible to refailure over the long term due to insufficient repair tissue formation. Similarly, fibrous scaffolds used in repair applications also impede cell infiltration when the scaffolds become too dense (6).

This raises an important conundrum in dense connective tissues and repair scaffolds; while the dense ECM and fibrous scaffold properties are critical for mechanical function, they, at the same time, can compromise cell migration, with endogenous cells locked in place and unable to participate in repair processes. This concept is supported by in vitro studies documenting that, in 3D collagen gels, the migration of mesenchymal lineage cells is substantially attenuated once the gel density and/or stiffness has reached a certain threshold (79). Consistent with this, our recent in vitro models exploring cell invasion into devitalized dense connective tissue (knee meniscus sections) showed reduced cellular invasion in adult tissues compared to less dense fetal tissues (3). The density of collagen in most adult dense connective tissues is 30 to 40 times higher than that used within in vitro collagen gel migration assay systems (2, 3), emphasizing the substantial barrier to migration that the dense ECM plays in these tissues.

To address this ECM impediment to successful healing, we and others have developed strategies to loosen the matrix (via local release of degradative enzymes) in an attempt to expedite repair and/or encourage migration to the wound site (10), with promising results both in vitro and in vivo (10, 11). Despite the potential of this approach, it is cognitively dissonant to disrupt ECM to repair it, and any such therapy would have to consider any adverse consequences on tissue mechanical function.

This led us to consider alternative controllable parameters that might regulate interstitial cell mobility while preserving the essential mechanical functionality of the matrix. It is well established that increasing matrix density decreases the effective pore size within dense connective tissues. The nucleus is the largest (and stiffest) organelle in eukaryotic cells (12), and it must physically deform as a cell passes through constructures that are smaller than its own smallest diameter (9). When artificial pores of decreasing diameter are introduced along an in vitro migration path (e.g., in an in vitro Boyden chamber system), cell motion can be completely arrested (13). If cells are forced to transit through these tight passages, then nuclear rupture and DNA damage can occur (14, 15). Conversely, under conditions where nuclear stiffness is low, as is the case in neutrophils (16) and some particularly invasive cancer cells (17), migration through small pores occurs quite readily.

Given the centrality of the nucleus in migration through small pores, methods to transiently regulate nuclear stiffness or deformability might therefore serve as an effective modulator of interstitial cell migration through dense tissues and scaffolds. Nuclear stiffness is defined by two primary featuresthe density of packing of the genetic material contained within (i.e., the heterochromatin content) and the intermediate filament network that underlies the nuclear envelope (the nuclear lamina, composed principally of the proteins Lamin B and Lamin A/C) (12, 16, 18, 19). Increasing chromatin condensation increases nuclear stiffness, while decreasing Lamin A/C content decreases nuclear stiffness (19, 20). Both increasing the stiffness of the microenvironment in which a cell resides (21) and the mechanical loading history of a cell promotes heterochromatin formation and Lamin A/C accumulation (2224), resulting in stiffer nuclei. Since both matrix stiffening and mechanical loading are features of dense connective tissue maturation, these inputs may drive nuclear mechanoadaptation (25), resulting in endogenous cells with stiff nuclei that are locked in place.

On this basis, the goal of this study was to determine whether nuclear softening could enhance migration through dense connective tissues and repair scaffolds to increase colonization of the wound site and the potential for repair by endogenous cells. We took the approach of transiently decreasing nuclear stiffness in adult meniscus cells through decreasing heterochromatin content [using Trichostatin A (TSA), a histone deacetylase (HDAC) inhibitor] that promotes chromatin relaxation (26) and confirmed the importance of nuclear stiffness by reducing Lamin A/C protein content (using lentiviral-mediated knockdown). Our experimental findings and theoretical models demonstrate that nuclear softening decreases the barriers to interstitial migration through small pores, both in vitro and in vivo, resulting in the improved colonization of dense fibrous networks and transit through native tissue by adult meniscus cells. By addressing the inherent limitations to repair imposed by nuclear mechanoadaptation that accompanies cell differentiation and ECM maturation, this work defines a promising strategy to promote the repair of damaged dense connective tissues in adults.

We first determined whether TSA treatment alters chromatin organization in adult meniscal fibrochondrocytes (MFCs). Super-resolution images of the core histone protein Histone-H2B in MFC nuclei were obtained by stochastic optical reconstruction microscopy (STORM) and revealed a notable organization of Histone-H2B inside MFC nuclei (STORM; Fig. 1A), which could not be observed with conventional microscopy (conventional; Fig. 1A). It has recently been shown that super-resolution images can be segmented at multiple length scales using Voronoi tessellation (27, 28). To segment the H2B super-resolution images, we carried out Voronoi tessellation, used a threshold to remove large polygons corresponding to regions of the nucleus containing sparse localizations, and color-coded the localizations with the same color if their polygons were connected in space and shared at least one edge. This segmentation showed that H2B localizations clustered to form discrete and spatially separated nanodomains in control nuclei [()TSA]. Nuclei treated with TSA, on the other hand, contained smaller domains. These results were quantitatively recapitulated by a decrease in the number of H2B localizations in individual domains and an overall decrease in the area of domains in MFCs treated with TSA [(+)TSA] (Fig. 1, B to D). These results are in line with a more folded chromatin confirmation in ()TSA cells, which opens and decondenses after TSA treatment. These results are also consistent with recent super-resolution analysis, which showed that TSA-treated fibroblasts have small nucleosome nanodomains that are more uniformly distributed in the nuclear space compared to control fibroblasts (29, 30). This decondensation was also confirmed in TSA-treated bovine mesenchymal stem cells (MSCs), where TSA treatment decreased the number and area of H2B nanodomains (fig. S1A). This increased acetylation at H3K9 (Ac-H3K9) was apparent at the nanoscale (fig. S1B) and via conventional fluorescence imaging of the nuclei (fig. S1C). Conversely, there were no significant changes in H3K27me3 with TSA treatment when evaluated using STORM or conventional fluorescent microscopy (fig. S1, D and E).

(A) Representative conventional fluorescent and STORM imaging of Histone-H2B in a control [top; ()TSA] or TSA-treated MFC nucleus [bottom; (+)TSA]. (B) Corresponding Voronoi-based image segmentation, which allows for visualization and quantification of Histone-H2B nanodomains. (C and D) Quantification of the number of H2B localizations per cluster and the cluster area with TSA treatment. The box, line, and dot correspond to the interdecile range (10th to 90th percentile), median, and mean, respectively, Mann-Whitney U test, n 10,584 clusters from five cells. Next to each Voronoi image, higher-magnification zoom-ins of the region inside the squares are shown. (E) TSA treatment for 3 hours decreases chromatin condensation in 4,6-diamidino-2-phenylindole (DAPI)stained nuclei (scale bar, 5 m), and the number of visible edges (left). Quantification of the chromatin condensation parameter (CCP) with TSA treatment [right; *P < 0.05 versus ()TSA, n = ~20]. (F) Schematic showing experimental design to evaluate nuclear deformability and changes in nuclear aspect ratio (NAR = b/a) with cell stretch. (G) Representative DAPI-stained nuclei on scaffolds before and after 15% stretch (left; scale bar, 20 m) and NAR at 3 and 15% stretch (n = 32 to 58 cells, *P < 0.05 versus ()TSA and +P < 0.05 versus 3%). (H) 2D wound closure assay shows no differences in gap filling in the presence or absence of TSA [()TSA; left: scale bar, 200 m; right: P > 0.05, n = 6). (I) Schematic of Boyden chamber chemotaxis assay (left) and migrated cell signal intensity through 3-, 5-, and 8-m-diameter pores, with and without TSA pretreatment [right; n = 5 samples per group, *P < 0.05 versus ()TSA and +P < 0.05 versus 3 m, means SD]. All experiments were carried out at least in triplicate, except for the wound closure assay (which was performed in duplicate). RFU, relative fluorescence units.

In addition, TSA treatment for 3 hours [(+)TSA] also resulted in marked chromatin decondensation in MFCs seeded on aligned (AL) nanofibrous scaffolds that are commonly used for dense connective tissue repair, as evidenced by decreases in the number of visible edges in 4,6-diamidino-2-phenylindole (DAPI)stained nuclei compared to control cells [()TSA] and a reduction (~40%) in the image-based chromatin condensation parameter (CCP) (Fig. 1E).

To assess whether this TSA-mediated chromatin decondensation changed nuclear stiffness and deformability, we stretched MFC-seeded AL scaffolds (from 0 to 15% grip-to-grip strain) and determined the change in nuclear aspect ratio (NAR) (Fig. 1F). Nuclei that were pretreated with TSA [(+)TSA] showed increased nuclear deformation compared to control nuclei [()TSA] (Fig. 1G); however, TSA did not change cell/nuclear morphology (fig. S2, A to C) or cell migration on planar surfaces (Fig. 1H), and only minor changes in focal adhesions were observed (fig. S2, D and E). MFC spread area and traction force generation were also unaffected by TSA treatment when cells were plated on soft substrates (E = 10 kPa) (fig. S2, F to I). These observations suggest that TSA treatment decreases nuclear deformability by chromatin decondensation without changing overall cell migration capacity in 2D culture.

We next assessed the ability of MFCs to migrate through small pores using a commercial transwell migration assay (Fig. 1I). Cells treated with TSA [(+)TSA] (200 ng/ml) showed enhanced migration compared to controls [()TSA] across all pore sizes, including 3-m pores that supported the lowest migration in controls (Fig. 1I). This improved migration with TSA treatment was dose dependent (fig. S3). Together, these data show that while TSA treatment does not change cell morphology, contractility, or planar migration on 2D substrates, chromatin relaxation increases MFC nuclear deformability, which improves cell migration through micron-sized pores.

Having observed increased migration through rigid micron-sized pores with nuclear softening, we next assayed whether TSA treatment would enhance migration through dense fibrillar networks. A custom microfluidic cell migration chamber was designed, consisting of a top reservoir containing basal medium (BM), a bottom reservoir containing BM supplemented with platelet-derived growth factor (PDGF) as a chemoattractant and an interposed nanofibrous poly(-caprolactone) (PCL) layer (labeled with CellTracker Red, ~150-m thickness) (Fig. 2, A and B). With this design, a gradient of soluble factors is presented across the fibrous layer, as evidenced by Trypan blue diffusion over time (Fig. 2C).

(A) Schematic (top) and a top view (bottom) of the PDMS [poly(dimethylsiloxane)]/nanofiber migration chamber. (B) Schematic showing meniscus cells (green) seeded onto fluorescently labeled nanofibers interposed between the top reservoir containing BM and a bottom reservoir containing BM supplemented with PDGF (100 ng/ml) as a chemoattractant. (C) Visual representation of soluble factor gradient in microdevice showing the slow accumulation of trypan blue in the upper chamber as a function of time. (D) Experimental schematic showing meniscus cell (MFC) isolation and seeding onto nanofiber substrates (passage 1, isolated from adult bovine menisci). One day after seeding, TSA or PDGF was added to the top reservoir or the bottom reservoir, respectively, and cells were cultured for additional 2 days. On day 3, scaffolds were imaged by confocal microscopy to determine the degree of cell penetrance into the scaffold. (E) 3D confocal reconstructions of cell (green) migration through AL or non-AL (NAL) nanofibrous networks (AL or NAL; red) with and without TSA treatment. Scale bar, 30 m. (F) Cross-sectional views of cells (green) within nanofibrous substrates (red). Scale bar, 30 m. Quantification of the percentage of infiltrated cells (G) [n = 5 to 8 images, *P < 0.05 versus ()TSA and +P < 0.05 versus AL, means SD] and cell infiltration depth (H) [n = 33 cells, *P < 0.05 versus ()TSA and +P < 0.05 versus AL, means SEM, normalized to the ()TSA/AL group]. Quantification of the percentage of infiltrated cells (I) [n = 5 images, *P < 0.05 versus ()TSA, P < 0.05 versus 0% poly(ethylene oxide) (PEO), and aP < 0.05 versus 25% PEO, means SD] and cell infiltration depth (J) [n = 33 cells, *P < 0.05 versus ()TSA, P < 0.05 versus 0% PEO, and aP < 0.05 versus 25% PEO, means SD] normalized to the control PCL/0% PEO group] as a function of PEO content. All experiments were carried out in triplicate.

MFCs were seeded atop the fibrous layer, and their migration was evaluated as a function of nuclear deformability (TSA) and fiber alignment [AL or non-AL (NAL)]. MFCs were cultured in BM for 1 day for attachment and then were treated for 2 days either with or without TSA (Fig. 2D). Confocal imaging (Fig. 2, E and F, and movie S1, A and B) and scanning electron microscopy (fig. S4A) showed increased MFC invasion into the fibrous networks with TSA treatment [(+)TSA] when compared to untreated MFCs [()TSA]. Without TSA, MFCs remained largely on the surface of the fibers with some cytoplasmic extensions into the fibers (fig. S4B), whereas TSA treatment increased the number of nuclei entering the fiber network (fig. S4C). When quantified, infiltration was higher in the NAL group compared to the AL group (P < 0.05; Fig. 2, G and H), likely due to the increased pore size in the NAL scaffolds (6, 31), and TSA treatment improved migration to similar levels in both NAL and AL groups (P < 0.05; Fig. 2, G and H). As expected, cells in AL scaffolds showed higher aspect ratios and solidity compared to cells on NAL scaffolds, yet TSA treatment did not influence cell morphology (fig. S4D). Nuclei in NAL groups were rounder (lower NAR) than in AL groups, and TSA treatment resulted in more elongated nuclei (higher NAR) in both AL and NAL groups (fig. S4E). While promoting cell invasion, TSA treatment did not result in any change in DNA damage (as assessed by phospho-histone H2AX-positive nuclei; fig. S4F) and slightly reduced cell proliferation at this time point (fig. S4G). Thus, it appears that TSA increased nuclear deformability, resulting in enhanced cell migration into these dense fibrous networks.

To verify that nuclear softening is the primary mechanism for enhanced migration into fibrous networks, we also knocked down Lamin A/C in MFCs before seeding. In previous studies, cells lacking Lamin A/C showed increased nuclear deformability and increased mobility in collagen gels and through small pores in Boyden chambers (13, 32). Consistent with these studies (12, 19, 33), reduction of Lamin A/C protein levels in MFCs and MSCs (fig. S5, A to C) increased nuclear deformability in response to applied stretch (fig. S5D). When MFCs with Lamin A/C knockdown were seeded onto fibrous networks, a greater fraction entered into the scaffold and reached greater infiltration depths (fig. S5, E to G). To further illustrate that nuclear stiffening reduces migration, we cultured MSCs in transforming growth factor3 (TGF-3)containing media for 1 week before seeding onto the fibers. As we reported previously (23), these conditions induce differentiation in MSCs, resulting in stiffer nuclei with increased chromatin condensation and decreased nuclear deformability. Compared to undifferentiated MSCs, these differentiated MSCs were found largely on the scaffold surface (fig. S6, A to D) and had a lower infiltration rate and depth. While many factors change during cell differentiation, these findings also support that a less deformable nucleus is an impediment to interstitial cell migration. Together, these studies support that a stiff nucleus is a limiting factor in the invasion of the small pores of dense fibrous networks.

To investigate the combined role of porosity and nuclear softening on migration, we next fabricated fibrous networks through the combined electrospinning of both PCL and poly(ethylene oxide) (PEO), where PEO acts as a sacrificial fiber fraction to enhance porosity (6, 31). Consistent with our previous findings, cell infiltration percentage and depth progressively increased as a function of increasing PEO content (Fig. 2, I and J). When nuclei were softened with TSA treatment, we observed greater infiltration into low-porosity scaffolds (PEO content, <25%), but no difference in high porosity scaffolds (Fig. 2, I and J). This suggests that increasing nuclear deformability is only beneficial in the context of dense networks, where the nucleus impedes migration.

To better define the relationship between pore size and nuclear stiffness on cellular migration, we developed a computational model to predict the critical force (Fc) required for the nucleus to enter a small channel (Fig. 3). This model was motivated by studies of cellular transmigration through endothelium in the context of cancer invasion, where the surrounding matrix properties (stiffness), endothelium properties (stiffness and pore size), and the cell properties (in particular, the nuclear stiffness) appear to regulate transmigration (34). Here, we considered cell migration into a narrow and long channel to mimic migration into a porous fiber network, where network properties are defined by fiber density (Fig. 3A). When the cell enters the channel, the resistance force encountered by the nucleus increases monotonically as the cell advances, reaching a maximal resistance force (defined as the critical force, Fc). Following this, the nucleus snaps through the opening, leading to a drop in the resistance force, which vanishes after the nucleus fully enters the channel (Fig. 3B and movie S2). Thus, the cells must generate a sufficient force to overcome this critical force to migrate into a channel. As the channel size (rg) becomes smaller and the ECM modulus (EECM) becomes greater, the critical force required for the nucleus to enter the channel increases (Fig. 3C and fig. S7). As this required force increases, it eventually exceeds the force generation capacity of the cell, resulting in a situation where the cell cannot enter the pore.

(A) Schematic showing a nucleus (blue) above a narrow channel representing the small pores in a dense fiber network (orange). The geometric parameters are the radius of the nucleus (rn) and the half width of the channel (rg). The stiffness parameters are the modulus of the nucleus (En) and the fiber network (EECM). The nucleus is treated as a spheroid for simplicity. (B) Simulation of a nucleus moving into and through the channel in the dense fiber network. The normalized resistant force (F/Enrn2) encountered by the nucleus is plotted as a function of the normalized displacement of the nucleus (un/rn). The maximum normalized resistance force is defined as the critical force. (C) The critical force as a function of the normalized ECM modulus (with respect to En) and normalized channel size (with respect to rn). The critical force is larger as the ECM becomes stiffer or the channel becomes smaller. (D) The critical force decreases as the PEO content increases. TSA treatment also decreases the critical force, particularly for dense networks (low PEO content). (E) Normalized NAR after entry into the channel increases as the ECM becomes stiffer or the nucleus becomes softer (both lead to a larger normalized ECM modulus, EECM/En).

To better understand the influence of PEO content (affecting both the channel size and ECM modulus) and dose of TSA (affecting nuclear modulus) on cell migration, we used the normalized critical force data obtained from the model. Our previous work (6) defined the influence of PEO content on matrix mechanical properties and pore size; the effect of TSA on nuclear stiffness has also been measured quantitatively by other groups (26). Using these data, we predicted the critical force at different PEO contents for both TSA-treated and control cells (Fig. 3D). Results from this model showed that critical force decreased monotonically as PEO content increased, given that a higher PEO content results in larger pores (31). This indicates that infiltrated cell numbers should increase as the PEO content increases, consistent with our experimental results. Likewise, since TSA results in a softer nucleus (26), the critical force drops significantly compared to control conditions. This is particularly important at low PEO contents (denser networks), where the critical force for TSA-treated nuclei drops markedly. In networks with larger pores, the difference in critical force between TSA-treated groups vanishes. We included the model to gain, in general, insight into how a change in nuclear deformability (with TSA) might broadly affect cell migration in 3D and chose a simple configuration to gain some initial insight. While this model is simple (i.e., it does not represent the geometry of our fiber networks or native tissue), its predictions were consistent with our experimental findings, where the percentage of infiltrated cells was higher with TSA treatment at 0% PEO but the difference between groups disappeared at 50% PEO (Fig. 2I). The model also predicted that the NAR (after fully embedded in the channel) should increase as the nucleus becomes softer or the ECM becomes stiffer [with both resulting in a larger normalized ECM modulus (Fig. 3E), EECM/En]; this also is consistent with our experimental results showing that the NAR of TSA-treated nuclei within scaffolds was larger than nuclei in the control group.

The above data demonstrate that TSA treatment decreases chromatin condensation for a sufficient period of time to permit migration. However, prolonged exposure to this agent may have deleterious effects on cell phenotype and function. To assess this, we queried how long changes in MFC nuclear condensation persist after TSA withdrawal. MFCs were treated with TSA for 1 day as above, followed by five additional days of culture in fresh BM (Fig. 4A). Consistent with our previous findings, TSA decreased chromatin condensation and CCP after 1 day of treatment (Fig. 4, B and C). Upon removal of TSA, CCP values progressively increased, reaching baseline levels by day 5 (Fig. 4, B and C). A similar finding was noted in H2B localizations and domain area via STORM imaging, where these values returned to baseline levels within 5 days of TSA withdrawal (fig. S8, A to C). Similarly, nuclei in MFCs treated with TSA showed increased deformation compared to control MFC nuclei that were not treated with TSA (Fig. 4D) and increased Ac-H3K9 levels (Fig. 4, E and F), but these values gradually returned to the baseline levels within 5 days with TSA removal (Fig. 4, D to F). Over this same time course, proliferation was decreased in TSA-treated cells but returned to baseline levels within 5 days of TSA withdrawal on both tissue culture plastic (TCP) and on AL nanofibrous scaffolds (fig. S8, D and E). No change in levels of apoptosis (caspase activity) was observed over this time course (fig. 8F). Further, to investigate phenotypic behavior of cells after TSA treatment in the context of tissue repair, we next assayed whether cells exposed to TSA showed alterations in fibrochondrogenic gene expression and collagen production in MFCs. Although the sample size was small in this study, we did not detect a significant change in gene expression for any of the major collagen isoforms or proteoglycans normally produced by meniscus cells (fig. S9A). To further assess this, MFCs were treated with TSA for 1 day, followed by culture in fresh BM or TGF-3 containing chemically defined media (to accelerate collagen production) for an additional 3 days. Collagen produced by these cells and released to the media was not altered by TSA treatment (fig. S9B). Together, these data support that TSA treatment decreases chromatin condensation by increasing acetylation of histones in MFCs but this change is transient and baseline levels are restored gradually after TSA is removed, without alterations in collagen production.

(A) Schematic showing experimental setup; adult MFCs seeded on AL nanofibrous scaffolds were treated with/without TSA in BM for 1 day, followed by culture in fresh BM without TSA for an additional 5 days. (B) Representative DAPI-stained nuclei (top) and corresponding detection of visible edges (bottom) (scale bar, 3 m) and (C) CCP for time points indicated in (A) (red line; BM control at day 0, n = ~20 nuclei, *P < 0.05 versus Ctrl, means SEM). (D) NAR with 3 and 15% of applied stretch (normalized to NAR with 0%, n = 65 ~80 cells, *P < 0.05 versus 3%, +P < 0.05 versus Ctrl, P < 0.05 versus day 0, and aP < 0.05 versus day1, means SEM). (E) Immunostaining for Ac-H3K9 (green) in nuclei (blue) and quantification of mean intensity of the immunostaining (F) (n = ~28 cells, *P < 0.05 versus Ctrl and +P < 0.05 versus day 0, means SEM]. a.u., arbitrary units. All experiments were carried out in triplicate.

Given that transient TSA treatment softened MFC nuclei, resulting in enhanced interstitial cell migration, and did not perturb collagen production in the short term, we next investigated longer-term maturation of a tissue engineered construct with TSA treatment. For this, MFCs were seeded onto AL-PCL/PEO 25% scaffolds and cultured in TGF-3 containing chemically defined media for 4 weeks with/without TSA treatments (once a week for 1 day) as illustrated in Fig. 5A. In controls [()TSA], collagen deposition occurred mostly at the construct border (Fig. 5B), but both deposition and cell distribution were improved with TSA treatment [(+)TSA] (Fig. 5, B and C). Quantification showed that ~50% of cells were located within 50 m of the scaffold edge in controls [()TSA], while TSA treatment [(+)TSA] increased the number of cells deeper within the scaffold (250- to 400-m range; Fig. 5D).

(A) Experimental schematic showing MFCs seeded on PCL/25% PEO nanofibrous scaffolds that were cultured in chemically defined media for 4 weeks with TSA treatment once per week. After 4 weeks, ECM production and cell infiltration with/without TSA treatment were evaluated. Representative cross sections of MFC-laden nanofibrous constructs at week 4 stained for collagen (B) and cell nuclei (C). Scale bar, 100 m. (D) Quantification of MFC infiltration with/without TSA treatment (n = 3 images from three separate samples, *P < 0.05 versus ()TSA, means SEM). Experiments were carried out in duplicate. PSR, Picrosirius Red.

Toward meniscus repair, it is important to evaluate MFC migration through the dense fibrous ECM of meniscus tissue in the context of TSA treatment. For this, adult meniscus explants (, 5 mm) were cultured for ~2 weeks, donor cells in these vital explants were stained with CellTracker, and the explants were placed onto devitalized tissue substrates and cultured for an additional 48 hours, with/without TSA treatment [(/+)TSA] (Fig. 6A). During this 48-hour period, the cells derived from the donor explants adhered to the tissue substrates (Fig. 6B). In control groups [()TSA], cells were found predominantly on the substrate surface, whereas TSA-treated MFCs were found below the substrate surface (Fig. 6, B and C). Quantification showed that both the percent infiltration and the infiltration depth were significantly greater with TSA treatment (Fig. 6D).

(A) Schematic showing processing of vital tissue explants and devitalized tissue sections for invasion assay. Cell migration from the vital tissue and infiltration into the devitalized tissue section were evaluated by confocal microscopy. (B) 3D reconstructions (scale bar, 200 m) and (C) cross-sectional views (scale bar, 50 m) of cells (green) migrating through the devitalized tissue sections (blue), with and without TSA treatment. (D) Quantification of the percentage of infiltrated cells [n = 6 images, *P < 0.05 versus ()TSA, means SD] and cell infiltration depth [n = ~40 cells, *P < 0.05 versus ()TSA, means SEM]. Experiments were carried out in triplicate. (E) Electrospinning schematic showing two independent fiber jets collected simultaneously onto a common rotating mandrel. Discrete fiber populations are composed of PEO containing TSA and PCL. (F) Experimental schematic showing meniscus cell seeding onto nanofiber substrates. One day after seeding, the composite PCL/PEO TSA-releasing (PPT) scaffold was added to the microfluidic chamber reservoir, and cells were cultured for an additional 2 days, followed by confocal imaging. (G) 3D confocal reconstructions of cell (green) migration through AL nanofibrous networks with and without scaffold-mediated TSA delivery (scale bar, 100 m) and quantifications of the percentage of infiltrated cells [n = 5 images, *P < 0.05 versus ()TSA, +P < 0.05 versus (+)TSA, and #P < 0.05 versus 100 ng, means SD; biomolecule loading (mass per scaffold) is based on electrospinning parameters and scaffold mass]. (H) Schematic of repair construct assembly and subcutaneous evaluation in a rat model. (I) Images of DAPI-stained nuclei (blue) at the center of repair constructs after 1 week of subcutaneous implantation, with and without TSA delivery. Dashed lines indicate tissue-scaffold interfaces; dotted lines indicate separation into outer one-third (A), middle (B), and inner one-third (C) sections for quantification. Scale bar, 300 m. (J) Number of cells within each region of the scaffold with and without biomaterial-mediated TSA release (n = 3 samples from three different animals, *P < 0.05 versus PCL/PEO).

Next, we developed an assay to evaluate endogenous cell migration within native tissue. For this, tissue explants (, 6 mm) were excised from adult menisci, and the cells on the periphery of the explants were devitalized using a two-cycle freeze-thaw process (freezing in 20C for 30 min, followed by thawing at room temperature for 30 min, repeated twice on day 2; fig. S10A). This resulted in a ring of dead cells at the periphery of the tissue and a vital core. Processed explants were then treated with TSA for 1 day (day 1) and cultured in fresh media for an additional 3 days (fig. S10A). At the end of culture, living cells along the explant border were quantified. In controls that had not been treated by freeze-thaw (Ctrl), live cells occupied the periphery (fig. S10, B and D). With the two-cycle freeze-thaw process, there was a significant decrease in the number of live cells in this region (fig. S10, B and D), while cells in the center of the explant remained vital (day 2; fig. S10, B and D). With TSA treatment [(+)TSA], the number of vital cells that had migrated from the vital core to the periphery was significantly increased (day 3; fig. S10, C and D).

Last, to demonstrate the clinical potential of these findings, we developed an integrated biomaterial implant system to improve tissue repair in vivo (10, 35) via TSA delivery (Fig. 6E). Here, TSA was released from the PEO fiber fraction of a composite nanofibrous scaffold when this fiber fraction dissolves when placed in an aqueous environment. To first demonstrate bioactivity of the scaffold, we directly included small segments of these TSA-releasing composite scaffolds in the top chamber of the microfluidic migration device to treat seeded MFCs (Fig. 6F). Consistent with findings from soluble delivery, the percentage of infiltrated cells increased with the addition of the TSA-releasing composite scaffold (Fig. 6G): scaffolds releasing ~200 ng of TSA resulted in similar cell migration as direct addition of TSA (200 ng/ml) to the chamber (Fig. 6G). These results show our ability to deliver TSA to the wound site in a controlled fashion. To determine whether these TSA-releasing scaffolds could improve interstitial migration of endogenous meniscus cells in an in vivo setting, we subcutaneously placed meniscal repair constructs in nude rats with empty (PCL/PEO) or TSA-releasing scaffolds (PCL/PEO/TSA) interposed between the cut surfaces and histologically evaluated cellularity of the tissue and implant at 1 week (Fig. 6H). Results showed that interfacial cellularity was markedly higher for repair constructs with the scaffolds releasing ~100 ng of TSA (PCL/PEO/TSA) compared to control scaffolds (PCL/PEO; Fig. 6I), with cells occupying the full thickness of the TSA-releasing scaffold (Fig. 6J). Together, these data indicate that biomaterial-mediated nuclear softening of endogenous meniscus cells increases their capacity for interstitial migration through the tissue and into the scaffold in an in vivo setting.

PCL nanofibrous scaffolds were fabricated via electrospinning as in (6). Briefly, a PCL solution (80 kDa; Shenzhen Bright China Industrial Co. Ltd., China; 14.3% (w/v) in 1:1 tetrahydrofuran and N,N-dimethylformamide) was extruded through a stainless steel needle (2.5 ml/hour, 18-gauge, charged to +13 kV). To form NAL scaffolds, fibers were collected on a mandrel rotating with a surface velocity of <0.5 m/s. For AL scaffolds, fibers were collected at a high surface velocity (~10 m/s) (36). In some studies, to enhance cell infiltration, PCL/PEO (PEO, 200 kDa; Polysciences Inc., Warrington, PA) composite AL fibrous scaffolds were produced by coelectrospinning two fiber fractions onto the same mandrel, as in (6). For this, solutions of PCL (14.3%, w/v) and PEO (10%, w/v, in 90% ethanol) were electrospun simultaneously onto a centrally located mandrel (~10 m/s, 2.5 ml/hour). Resulting composite scaffolds were produced with PEO content of 0, 25, and 50% by scaffold dry mass. To visualize fibers, CellTracker Red (0.0005%, w/v) was mixed into the PCL solutions before electrospinning. Scaffolds were hydrated and sterilized in ethanol (100, 70, 50, and 30%; 30 min per step) and incubated in a fibronectin (20 g/ml) solution overnight to enhance initial cell attachment. TSA-releasing scaffolds contained a semipermanent (very slow degrading) fiber population (PCL) and a transient (water soluble) fiber population (PEO). The PEO fibers released TSA as they dissolve. To form this fiber fraction, TSA was added to the PEO solution (1% wt/vol) 2 days before spinning. PCL (10 ml) and PEO/TSA (10 ml) solutions were loaded into individual syringes and electrospun simultaneously by coelectrospinning onto a common centrally located mandrel, as above. Estimates of TSA content (mass per scaffold) were based on electrospinning parameters and the mass of each fiber fraction (Fig. 6E).

MFCs were isolated from the outer zone of adult bovine (20 to 30 months; Animal Technologies Inc.) or porcine menisci (6 to 9 months; Yucatan, Sinclair BioResources). For this, meniscal tissue segments were minced into ~1-mm3 cubes and placed onto TCP and incubated at 37C in a BM consisting of Dulbeccos modified Eagles medium (DMEM) with 10% fetal bovine serum and 1% penicillin/streptomycin/fungizone (PSF). Cells gradually emerged from the small tissue segments over 2 weeks, after which the remaining tissue was removed and the cells were passaged one time before use. MSCs were isolated from juvenile bovine bone marrow as in (37) and expanded in BM. To induce MSC fibrochondrogenesis, passage 1 MSCs were seeded on AL PCL scaffolds and cultured in a chemically defined serum free medium consisting of high glucose DMEM with 1 PSF, 0.1 M dexamethasone, ascorbate 2-phosphate (50 g/ml), l-proline (40 g/ml), sodium pyruvate (100 g/ml), insulin (6.25 g/ml), transferrin (6.25 g/ml), selenous acid (6.25 ng/ml), bovine serum albumin (BSA; 1.25 mg/ml), and linoleic acid (5.35 g/ml) (Life Technologies, NY, USA). This base medium (Ctrl) was further supplemented with TGF-3 (10 ng/ml) to induce differentiation (Ctrl/Diff, R&D Systems, Minneapolis, MN). Cell-seeded constructs were cultured in this medium for up to 7 days.

MFCs or MSCs were plated into eight-well Lab-Tek 1 cover glass chambers (Nunc), followed by preculture in BM for 2 days. At this time point, cells were treated with TSA for 3 hours, followed by fixation in methanol-ethanol (1:1) at 20C for 6 min. After a 1-hour incubation in blocking buffer containing 10 weight % BSA (Sigma-Aldrich) in phosphate-buffered saline (PBS), samples were incubated overnight with anti-H2B (1:50; abcam1790, Abcam), anti-H3K4me4 (1:100; MA5-11199, Thermo Fisher Scientific), or anti-H3K27me3 (1:100; PA5-31817, Thermo Fisher Scientific) at 4C. Next, samples were washed and incubated for 40 min with secondary antibodies custom labeled with activator-reporter dye pairs (Alexa Fluor 405Alexa Fluor 647, Invitrogen) for STORM imaging (29, 38). All imaging experiments were carried out with a commercial STORM microscope system from Nikon Instruments (N-STORM). For imaging, the 647-nm laser was used to excite the reporter dye (Alexa Fluor 647, Invitrogen) to switch it to the dark state. Next, a 405-nm laser was used to reactivate the Alexa Fluor 647 in an activator dye (Alexa Fluor 405)facilitated manner. An imaging cycle was used in which one frame belonging to the activating light pulse (405 nm) was alternated with three frames belonging to the imaging light pulse (647 nm). Imaging was carried out in a previously described imaging buffer [Cysteamine (#30070-50G, Sigma-Aldrich), GLOX solution: 1 glucose oxidase (0.5 mg/ml), 1 catalase (40 mg/ml) (all from Sigma-Aldrich), and 10% glucose in PBS] (39). STORM images were analyzed and rendered using custom-written software (Insight3, gift of B. Huang, University of California, San Francisco, USA) as previously described (39). For quantitative analysis, a previously described method was adapted that segments super-resolution images based on Voronoi tessellation of the fluorophore localizations (27, 28). Voronoi tessellation of a STORM image assigns a Voronoi polygon to each localization, such that the polygon area is inversely proportional to the local localization density (40). The spatial distribution of localizations is represented by a set of Voronoi polygons such that smaller polygon areas correspond to regions of higher density. Domains were segmented by grouping adjacent Voronoi polygons with areas less than a selected threshold, and imposing a minimum of three localizations per domain criteria generates the final segmented dataset.

MFCs (P1) were seeded onto AL PCL (0% PEO) scaffolds in BM for 2 days. To induce chromatin decondensation, TSA, a HDAC inhibitor (26) was added to the media for 3 hours. Chromatin condensation state and nuclear deformability were evaluated 3 hours after TSA treatment. For chromatin condensation analysis, constructs were fixed in 4% paraformaldehyde for 30 min at 37C, followed by PBS washing and permeabilization (with 0.05% Triton X-100 in PBS supplemented with 320 mM sucrose and 6 mM magnesium chloride). Nuclei were visualized by DAPI (ProLong Gold Antifade Reagent with DAPI, P36935, Molecular Probes, Grand Island, NY) and imaged at their mid-section using a confocal microscope (Leica TCS SP8, Leica Microsystems Inc., IL). Edge density in individual nuclei was measured using a Sobel edge detection algorithm in MATLAB to calculate the CCP as described in (24).

To assess nuclear deformability, the NAR (NAR = a/b) was evaluated before (0%) and after 9 and 15% grip-to-grip static deformation of constructs. Nuclear shape was captured on an inverted fluorescent microscope (Nikon T30, Nikon Instruments, Melville, NY) equipped with a charge-coupled device camera at each deformation level. NAR was calculated using a custom MATLAB code. Changes in NAR were tracked for individual MSC nuclei at each strain step as in (41).

To assess MFC migration on 2D substrates, a scratch assay was performed with or without TSA treatment. For this, passage 1 MFCs were plated into a six-well tissue culture dish (2 105 cells per well) and cultured to confluence (for 2 to 3 days). Confluent monolayers were then scratched with a 2.5-l pipette tip, and cell debris was removed via PBS washing. Images were taken using an inverted microscope at regular intervals and wound closure computed using ImageJ.

In addition, as an initial assessment of MFC migration, 96-well transwell migration assay kits (Chemicon QCM 96-well Migration Assay; membrane pore size, 3, 5, or 8 m) were used to assess cell migration. Briefly, human recombinant PDGF-AB (100 ng/ml in 150 l of BM; Prospect Bio) was added to the bottom chamber, and passage 1 MFCs (50,000 cells per well) were seeded into the top chamber. Cells were allowed to migrate for 18 hours at 37C with/without TSA treatment. In some studies, different dosages of TSA (0 to 800 nM) were applied (at a pore size of 5 m).

To assess initial cell migration through dense nanofiber networks, a custompoly(dimethylsiloxane) (PDMS) migration assay chamber was implemented (Fig. 2A). Top and bottom pieces containing holes (top, 6, 7, 6 mm in diameter; bottom, 6, 5, 6 mm in diameter) and a channel (bottom, 2 mm in width and 20 mm in length) were designed via SOLIDWORKS software for 3D printed templates (Acura SL 5530, Protolabs), and these were cast from the templates with PDMS (Sylgard 184, Dow Corning). To assemble the multilayered chamber, bottom PDMS pieces, the periphery of PCL electrospun fiber networks, and top PDMS pieces were coated with uncured PDMS base and curing agent mixture (10:1 ratio) and placed on cover glasses sequentially. For firm adhesion of each layer, chambers were incubated at 40C overnight. The final device consisted of a top reservoir containing BM and a bottom reservoir containing BM + PDGF (100 ng/ml) as a chemoattractant (Fig. 2A). To simulate chemoattactant diffusion from bottom to top reservoirs, trypan blue 0.4% solution (MP Biomedicals) was introduced to one of the side holes to fill the bottom reservoir, and the central top reservoir was filled with PBS. Cell migration chambers were kept in incubator (37C, 5% CO2), and images were obtained at regular intervals (Fig. 2D).

Fluorescently labeled (CellTracker Red) AL or NAL nanofibrous PCL scaffolds (thickness, ~150 m) were interposed between the reservoirs, and MFCs (2000 cells, passage 1) were seeded onto the top of each scaffold, followed by 1 day before culture in BM. Cells in chambers were cultured in BM with/without TSA for an additional 2 days. At the end of 3 days, cells were fixed and visualized by actin/DAPI staining. Confocal z-stacks were obtained at 40 magnification, and maximum z-stack projections were used to assess cellular morphology (cell/nuclear aspect ratio, area, circularity, and solidity). The percentage of infiltrated cells was quantified from confocal z stacks, with cells located beneath fibers categorized as infiltrated (fig. S3C) and the infiltration depth measured on cross-sectional images using ImageJ. For scanning electron microscopy imaging, additional samples were fixed and dehydrated in ethanol (30, 50, 70, and 100%, 60 min per step) and then hexamethyldisilane for terminal dehydration under vacuum.

Details on the model have been described previously (34). Briefly, to understand the influence of both intracellular and extracellular cues on cell migration through the fibrous ECM, we considered a model in which a cell with a spherical nucleus of radius rn is invading ECM through a deformable gap (with radius rg) smaller than the diameter of the nucleus (Fig. 3A). For simplicity, the nucleus is modeled by a spheroid and treated as a compressible neo-Hookean hyperelastic material to capture the mechanical response. An infinitely long small channel is created in the ECM to mimic the path a cell would migrate through in the migration assay. A neo-Hookean hyperelastic material was used to capture the ECM mechanical properties. The model parameters are shown in Table 1.

To assess how fast the TSA-mediated MFC chromatin organization and deformability was restored after TSA removal, MFCs seeded on AL scaffolds were treated with TSA for 1 day, followed by additional culture for 5 days in fresh BM (Fig. 4A). At each time point, the CCP and nuclear deformability were evaluated as described above. In addition, Ac-H3 levels in MFC nuclei were assessed by immunostaining with an Ac-H3K9 monoclonal antibody (MA5-11195, Thermo Fisher Scientific; 1:400, overnight at 4C). All images were collected using a confocal microscope (Leica TCS SP8, Leica Microsystems Inc., IL) at 63 magnification, with staining intensity quantified using ImageJ.

For long-term evaluation of matrix production after TSA treatment, MFCs were seeded on PCL/PEO 25% AL nanofibrous scaffolds (P1, 105 cells, 1 cm by 1 cm by 0.1 cm) and were cultured in TGF-3 containing chondrogenic media for 4 weeks. TSA was applied once each week for 24 hours. After 4 weeks, constructs were fixed with 4% paraformaldehyde and embedded in CryoPrep frozen section embedding medium [optimal cutting temperature (OCT) compound, Thermo Fisher Scientific, Pittsburgh, PA]. Using a cryostat microtome (Microm HM-500 M Cryostat, Ramsey, MN), constructs were sectioned to 8 m in thickness through their depth and stained with Picrosirius Red and DAPI to visualize collagen and nuclei, respectively. Stained sections were visualized and imaged by brightfield and fluorescent microscopy (Nikon Eclipse TS 100, Melville, NY). To quantify cell infiltration in the scaffolds, the number of migrated cells as a function of scaffold depth was determined for each experimental group (n = 3 scaffolds per group) using ImageJ.

To isolate fresh MFCs, cylindrical tissue explants (6 mm in diameter and 3 mm in height) were excised using biopsy punches from the middle zone of the meniscus, and these explants incubated in BM for ~2 weeks to allow cells to occupy the periphery. To fabricate devitalized tissue substrates, additional cylindrical tissue explants (8 mm in diameter) were embedded in OCT sectioning medium (Sakura Finetek, Torrance, CA) and axially cut (to ~50 m in thickness) using a cryostat microtome. These devitalized sections were placed onto positively charged glass slides and stored at 20C until use. After ~2 weeks of in vitro culture, the living explants were incubated in 5-chloromethylfluorescein diacetate (5 g/ml) (CellTracker Green, Thermo Fisher Scientific, Waltham, MA) in serum-free media (DMEM with 1% PSF) for 1 hour to fluorescently label cells in the explants. The explants were placed atop tissue substrates to allow for cell egress onto and invasion into the sections, and slides with explants were incubated at 37C with/without TSA treatment in BM for 2 days, at which point maximum z-stack projections were acquired using a confocal microscope (Leica TCS SP8, Leica Microsystems Inc., IL). Cell infiltration depth was measured as the distance between the apical tissue surface and the basal cell surface using a custom MATLAB code (3), and the total number of cells and the number of migrated cells (those entirely embedded within the tissue) were counted (n = 3 per group) using ImageJ.

In addition, to observe endogenous meniscus cell migration in the native ECM, a tissue-based migration assay was developed. Cylindrical meniscus tissue explants (6 mm in diameter and ~6 mm in height) were excised from the middle zone of adult menisci. To kill the cells on the border of the tissue, explants were frozen at 20C for 30 min and then thawed at room temperature for 30 min; this process was repeated twice (two-cycle) (day 2; fig. S10A). After devitalizing the periphery, explants were cultured in BM for 1 day, and TSA was added for 1 day (day 1; fig. S10A). After TSA treatment, explants were washed with PBS (day 0; fig. S10A), followed by culture in fresh BM for an additional 3 days. At day 3, LIVE/DEAD staining was performed, and explants cross sections were imaged (day 3; fig. S10A). Images were acquired from eight regions distributed evenly around the boundary (Leica TCS SP8, Leica Microsystems Inc., IL). The number of live cells located within 1 mm of the boundary was determined using ImageJ.

To evaluate the impact of biomaterial-mediated TSA delivery on endogenous meniscus cell migration in an in vivo setting, a nude rat xenotransplant model was used, as in (10). All animal procedures were approved by the Animal Care and Use Committee of the Corporal Michael Crescenz VA Medical Center. Before subcutaneous implantation, horizontal defects were created in adult bovine meniscal explants (8 mm in diameter and 4 mm in height, n = 3 donors; Fig. 6H). Electrospun PCL/PEO scaffolds with/without TSA were prepared (6 mm in diameter with a 2-mm-diameter central fenestration). Control PCL/PEO scaffolds or scaffolds releasing TSA (PCL/PEO/TSA, ~100 ng) were placed into the defect, which was closed with absorbable sutures. The repair construct was implanted subcutaneously into the dorsum of male athymic nude rats (n = 3, Hsd:RH-Foxn1rnu, 8 to 10 weeks old, ~300 g, Harlan) (Fig. 6H) (10). At 1 week, rats were euthanized, and constructs were removed from the subcutaneous space. Samples were fixed with para-formaldehyde and embedded in OCT sectioning medium (Sakura Finetek, Torrance, CA), sectioned to 8 m in thickness, stained with DAPI for cell nuclei, and imaged using a fluorescence microscope. Cell number in the center and edges of the implanted scaffold were determined using ImageJ.

Statistical analysis was performed using Student t tests or analysis of variance (ANOVA) with Tukeys honestly significantly different post hoc tests (SYSTAT v.10.2, Point Richmond, CA). For datasets that were not normally distributed, nonparametric Mann-Whitney or Kruskal-Wallis tests were performed, followed by post hoc testing with Dunns correction using GraphPad Prism version 6 (GraphPad Software Inc., La Jolla, CA, USA). Results are expressed as the means SEM or SD, as indicated in the figure legends. Differences were considered statistically significant at P < 0.05.

Acknowledgments: We acknowledge S. Gullbrand, D. H. Kim, and E. Henning for technical support. Funding: This work was supported by the NIH (R01 AR056624), the Department of Veterans Affairs (I01 RX000174), the NSF Science and Technology Center for Engineering Mechanobiology (CMMI-1548571), and the Penn Center for Musculoskeletal Disorders (P30 AR069619). Author contributions: S.-J.H., K.H.S., S.T., X.C., A.P.P., B.N.S., F.Q., V.B.S., M.L., J.A.B., and R.L.M. designed the studies. S.-J.H., K.H.S., S.T., X.C., A.P.P., and B.N.S. performed the experiments. S.-J.H., K.H.S., S.T., X.C., A.P.P., B.N.S., F.Q., V.B.S., M.L., J.A.B., and R.L.M. analyzed and interpreted the data. S.-J.H., S.T., X.C., V.B.S., M.L., J.A.B., and R.L.M. drafted the manuscript, and all authors edited the final submission. Competing interests: The authors declare that they have no competing interests. Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Additional data related to this paper may be requested from the authors.

Read the rest here:
Nuclear softening expedites interstitial cell migration in fibrous networks and dense connective tissues - Science Advances

Induced Pluripotent Stem Cells Market 2020 Global Industry …

The MarketWatch News Department was not involved in the creation of this content.

Jun 18, 2020 (The Expresswire) -- Induced Pluripotent Stem Cells Market 2020 Global Industry Trends, Size, Share Analysis Report. According to this report Global Induced Pluripotent Stem Cells Market will rise from Covid-19 crisis at moderate growth rate during 2020 to 2026. Induced Pluripotent Stem Cells Market includes comprehensive information derived from depth study on Induced Pluripotent Stem Cells Industry historical and forecast market data. Global Induced Pluripotent Stem Cells Market Size To Expand moderately as the new developments in Induced Pluripotent Stem Cells and Impact of COVID19 over the forecast period 2020 to 2026.

Induced Pluripotent Stem Cells Market report provides depth analysis of the market impact and new opportunities created by the COVID19/CORONA Virus pandemic. Report covers Induced Pluripotent Stem Cells Market report is helpful for strategists, marketers and senior management, And Key Players in Induced Pluripotent Stem Cells Industry.

Get Sample Report To Know How COVID-19 Impacting Induced Pluripotent Stem Cells Market

Global Induced Pluripotent Stem Cells Market Insights:

Report Analyzes Global Induced Pluripotent Stem Cells Market Growth Size, Share And Trends By Derived Cell Type (Amniotic cells, Fibroblasts, Keratinocytes, Hepatocytes, Others), By Application (Regenerative medicines, Drug development, Toxicity testing, Reprogramming technology, Academic research, Others), By End-user (Hospitals, Education and research institutes, Biotechnological companies) and Geography Forecast till 2026.

Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are: Astellas Pharma, Ncardia, Applied StemCell, FUJIFILM Cellular Dynamics, Axol Bioscience, Bristol-Myers Squibb Company, RandD Systems, Fate Therapeutics, Evotec AG, ViaCyte Inc.

STEMCELL Technologies Inc., a global biotechnology company launched mTeSR Plus, an enhanced version of mTeSR1, a widely published feeder-free human pluripotent stem cell (hPSC) maintenance medium. mTeSR Plus will be used to prevent onset acidosis. The launch of mTeSR Plus is likely to encourage global induced pluripotent stem cells growth owing to the design of the mTeSR Plus, which offers more consistent cell culture environment through sustained medium pH and stabilized components including FGF2. Furthermore, warning by FDA for marketing dangerous unapproved stem cells products is expected to alert pharmaceutical companies to market FDA approved products. This factor will, in turn, enable growth of the global induced pluripotent stem cells. For instance, the U.S Food and Drug Administration (FDA) sent a warning to Genetech, Inc. for marketing stem cell therapy without the U.S FDA approval and nonconformity of Good Manufacturing Practice (CGMP).

Active government support for RandD activities through research grants is driving the global induced pluripotent stem cells. Increasing private funding and rising shift towards regenerative medicines are predicted to favor induced pluripotent stem cells revenue. Further, induced pluripotent stem cells have created new avenues in clinical research, regenerative medicines, and disease modeling. This has also paved the way to numerous mergers and acquisitions and potential pipeline products and patents. In addition, the diversity of donor candidates is a factor predicted to aid induced pluripotent stem cells growth. Moreover, increasing accessibility towards the cell of origin is also expected to boost the global induced pluripotent stem cells market in the forthcoming year. However, ethical issues related to the donors and potential risk of tumors are factors predicted to hamper the growth of the global induced pluripotent stem cells.

Regional Market Overview:

Regional analysis is another highly comprehensive part of the research and analysis study of the global market presented in the report. This section sheds light on the sales growth of different regional and country-level markets. For the historical and forecast period to 2024, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global market.

Geographically, the global induced pluripotent stem cells market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America is expected to dominate the global induced pluripotent stem cells market during the forecast period due to the increasing RandD investment by key players for potential pipeline products. In Europe, the global induced pluripotent stem cells market is anticipated to grow significantly during the forecast period. The active government support and product launches are predicted to favor growth in the region. For instance, in 2018, Ncardia, a company working for drug discovery using stem cell, launched Xpress.4U LightPace Cor.4U, a kit for improving and simplifying the use of optical pacing of cardiomyocytes, a human induced pluripotent stem cell. The aforementioned factors together are enabling growth in Europe.

Intended Audience:

Competitive Analysis:

The Induced Pluripotent Stem Cells Market report examines competitive scenario by analyzing key players in the market. The company profiling of leading market players is included this report with Porter's five forces analysis and Value Chain analysis. Further, the strategies exercised by the companies for expansion of business through mergers, acquisitions, and other business development measures are discussed in the report. The financial parameters which are assessed include the sales, profits and the overall revenue generated by the key players of Market.

Inquire More Information On This Report

Report Highlights:

In-depth information about the latest Induced Pluripotent Stem Cells Industry trends, opportunities, and challenges.

Extensive analysis of the growth drivers And barriers.

Competitive landscape consisting of investments, agreements, contracts, novel product launches, strategic collaborations, and mergers and acquisitions.

List of the segments and the niche areas.

Comprehensive details about the strategies that are being adopted by key players.

Table of Content:

1.1. Research Scope

1.2. Market Segmentation

1.3. Research Methodology

1.4. Definitions and Assumptions

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities

4.1. Prevalence of Key Indications, 2017 (Key Countries)

4.2. Economic (Key Countries)

4.3. Key Mergers and Acquisitions

4.4. Pricing Analysis, Key Players, 2017

4.5. Overview: New Developments in Induced Pluripotent Stem Cells

5.1. Key Findings / Summary

Continue...

Related News:

Kidney Stone Management Devices Market Report

Pleural Effusion Treatment Market Report

Dental Chairs Market Report

Artificial Intelligence in Healthcare Market Report

Atopic Dermatitis Treatment Market Report

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights, we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune -411045, Maharashtra, India.

US: +1 424 253 0390

UK: +44 2071 939123

APAC: +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Press Release Distributed by The Express Wire

To view the original version on The Express Wire visit Induced Pluripotent Stem Cells Market 2020 Global Industry Analysis By Size, Growth Rate and Trends With Forecast To 2026

COMTEX_367053946/2598/2020-06-18T06:10:46

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

The MarketWatch News Department was not involved in the creation of this content.

Continued here:
Induced Pluripotent Stem Cells Market 2020 Global Industry ...

Hemophilia Treatment Market 2020 By End-User Demand, Emerging Trend, New Innovations, Future Prospect, Detailed Analysis and Forecast 2027 – 3rd Watch…

Hemophilia Treatment Market In-Depth Analysis, Regional Outlook

Hemophilia is a condition where blood does not clot, and this condition is normally inherited. The condition is caused due to defects in a gene of the X chromosome, which is a clotting factor. Generally, the diseases are widely seen in males as the X chromosome is inherited from mother to baby boy. The disease is widely treated with replacement therapy and gene therapy. The other treatment which is used is medication. However, there are ways to reduce the risk of the condition, which include regular exercise and others. The condition can be prevented by taking preventive treatment by injection of clotting factor VIII for hemophilia A, or IX for hemophilia B.

The hemophilia treatment market was valued at US$ 14,454.81 million in 2019 and is expected to grow at a CAGR of 15.9% from 2020 to 2027 to reach US$ 44,089.71 million by 2027.

Request Sample Copy of Hemophilia Treatment Market at:https://www.theinsightpartners.com/sample/TIPRE00008241/

Some of the key players profiled in the study areBayer AG, Sanofi, F. Hoffmann-la Roche Ltd., Kedrion S.P.A., CSL Limited, Biotest AG, Pfizer Inc., Novo Nordisk A/S, Octapharma AG, Baxter International Inc., etc.

Hemophilia Treatment Market Trends, Growth, Future Scope

Based on end user, the hemophilia treatment market is segmented into hospitals & clinics, hemophilia treatment centers, and ambulatory surgical centers. The hospitals and clinics held the largest share of end user segment in the global market. Moreover, the same segment is expected to grow at the fastest rate during the coming years. The hospital is a complex organization or an institute that provides health to people through complicated but specialized scientific equipment. The team of trained staff in the hospital, educated in the problems of modern medical science. They are all coordinated together for the common goal of restoring and maintain good health. Medical research is constantly pushing the boundaries of health care and redefining what is and isnt possible. The hospitals offer advanced treatment options as a resource for patients for chronic and hard-to-heal wounds and surgeries to treat them. Most of the surgeries are being performed in hospitals, owing to continuous patient care and monitoring. Also, increasing government funding in the hospitals and rising hospital research drives the market growth.

The research provides answers to the following key questions:

The report profiles the key players in the industry, along with a detailed analysis of their individual positions against the global landscape. The study conducts SWOT analysis to evaluate strengths and weaknesses of the key players in the Hemophilia Treatment market. The researcher provides an extensive analysis of the Hemophilia Treatment market size, share, trends, overall earnings, gross revenue, and profit margin to accurately draw a forecast and provide expert insights to investors to keep them updated with the trends in the market.

Competitive scenario:

The study assesses factors such as segmentation, description, and applications of Hemophilia Treatment industries. It derives accurate insights to give a holistic view of the dynamic features of the business, including shares, profit generation, thereby directing focus on the critical aspects of the business.

Global Hemophilia Treatment Market By Product

Global Hemophilia Treatment Market By Disease

Global Hemophilia Treatment Market By Treatment Type

Global Hemophilia Treatment Market By Therapy

Global Hemophilia Treatment Market By End User

Global Hemophilia Treatment Market By Geography

Major highlights of the report:

All-inclusive evaluation of the parent market

Evolution of significant market aspects

Industry-wide investigation of market segments

Assessment of market value and volume in past, present, and forecast years

Evaluation of market share

Study of niche industrial sectors

Tactical approaches of market leaders

Lucrative strategies to help companies strengthen their position in the market

Interested in purchasing this Report? Click here @https://www.theinsightpartners.com/buy/TIPRE00008241/

Thanks for reading this article; you can also customize this report to get select chapters or region-wise coverage with regions such as Asia, North America, and Europe.

About Us:

The Insight Partnersis a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are committed to provide highest quality research and consulting services to our customers. We help our clients understand the key market trends, identify opportunities, and make informed decisions with our market research offerings at an affordable cost.

We understand syndicated reports may not meet precise research requirements of all our clients. We offer our clients multiple ways to customize research as per their specific needs and budget

Contact Us:

The Insight Partners,

Phone: +1-646-491-9876

Email:[emailprotected]

Read the rest here:
Hemophilia Treatment Market 2020 By End-User Demand, Emerging Trend, New Innovations, Future Prospect, Detailed Analysis and Forecast 2027 - 3rd Watch...

Biobanking Market to Reach $49.46 Billion by 2026; Recent Breakthrough Concepts have Indicated Potential in Covid-19 Vaccine, says Fortune Business…

Pune, June 18, 2020 (GLOBE NEWSWIRE) -- The global biobanking market size is projected to reach USD 49.46 billion by the end of 2026. The growing investments in development of efficient biobanks and recent studies associated with the use of biobanks in the treatment of the coronavirus will emerge in favor of market growth. According to a report published by Fortune Business Insights, titled "Biobanking Market Size, Share & Industry Analysis, By Sample Storage (Blood, Cells & Tissue, and Others), By Application (Regenerative Medicines, Life Sciences, and Others), By Settings (Academic Medical Institutes, and Pharmaceutical & Biotechnology Companies), and Regional Forecast, 2019-2026," the market was worth USD 25.09 billion in 2018 and will exhibit a CAGR of 8.9% till 2026.

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/biobanking-market-102073

Biobanking Can Play a Huge Role in Fighting the Coronavirus

The constant research and collective studies associated with the coronavirus speaks volumes about the seriousness and severity of the disease. It is observed that biobanking has shown potential in the development of treatment options for Covid-19. This will present several growth opportunities for the companies operating in the market.

Biobanking refers to the process wherein blood samples are collected and studied for research and development purposes. This process helps in understanding the cause and effect of several diseases and can also help produce efficient treatment methods for specific diseases through prolonged research and study. The increasing emphasis on biobanking is consequential to the excellent results and outputs in recent years.

As a result, massive investments are being made in the development of efficient processes, with the aim of studying severe and critical diseases. The study of blood can also aid in the health and nutritional requirement s in the human body. Technological advancements have allowed applications such as tracking and real-time examination; a process that has hugely benefited the global biobanking market in recent years.

An Overview of the Impact of COVID-19 on this Market:

The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.

We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.

To get the short-term and long-term impact of COVID-19 on this Market.

Please visit: https://www.fortunebusinessinsights.com/biobanking-market-102073

United Kingdom Announces $247 DNA Database

The report encompasses several factors that have contributed to the growth of the overall market in recent years. Accounting to the increasing applications of biobanking in several research and studies, there has been a surge in the overall investments in product R&D. The growing investments in product R&D will have a direct impact on the growth of the market in the coming years. In September 2019, the UK announced that it has invested a huge sum in a new database for the Genome Decoding Research Project.

The UK announced USSD 247 million for the project. Through this activity, it will analyze and sequence the genetic codes of 500,000 volunteers. Large scale healthcare and pharma companies such as GlaxoSmithKline plc and Johnson & Johnson are also involved in the project. The high investments in the development of large scale biobank projects similar to this, will have a direct impact on the growth of the overall market in the coming years.

Quick Buy - Biobanking Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/102073

Europe Currently Dominates the Market; Presence of Well-established Biobanks will Aid Growth

The report analyses the latest market trends across five major regions, including North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Among all regions, the market in Europe currently dominates the market. The presence of numerous large scale biobanks in Nordic countries such as Sweden, Denmark, and Norway will contribute to the growth of the market in this region.

It is recorded that around 40% of the total population in Iceland have contributed DNA samples; a factor that will be influential to the growth of the regional market. As of 2018, the market in Europe was worth USD 8.93 billion and this value is projected to increase at a considerable pace in the coming years. The market in Asia Pacific is projected to register a considerable CAGR driven by the high investment in establishing well-structured biobanks.

List of Leading Companies Profiled in the Biobanking Market Report are:

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/biobanking-market-102073

Detailed Table of Content:

TOC Continued.!!!

Request for Customization: https://www.fortunebusinessinsights.com/enquiry/customization/biobanking-market-102073

Have a Look at Related Reports:

Regenerative Medicine Market Size, Share and Industry Analysis By Product (Cell Therapy, Gene Therapy, Tissue Engineering, Platelet Rich Plasma), By Application (Orthopaedics, Wound Care, Oncology), By Distribution Channel (Hospitals, Clinics) & Regional Forecast, 2019 - 2026

Hemostats Market Size, Share & Industry Analysis, By Product Type (Active Hemostats, Passive Hemostats, Combination Hemostats, Others), By Application (Trauma, Cardiovascular Surgery, General Surgery, Plastic Surgery, Orthopedic Surgery, Neurosurgery, Others), By End User (Hospitals, Ambulatory Surgical Centers, Tactical Combat Casualty Care Centers, Others) and Regional Forecast, 2018-2025

Non-Hodgkin Lymphoma Treatment Market Size, Share & Industry Analysis, By Therapy (Immunotherapy, Targeted Therapy, Chemotherapy, and Others), By Disease Type (B-cell Lymphoma, and T-cell Lymphoma), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, and Online Pharmacies), and Regional Forecast, 2019-2026

Active Pharmaceutical Ingredient (API) Market Size, Share & Industry Analysis, By Type (Generic API, and Branded API), By Synthesis (Biological API, and Synthetic API), and Regional Forecast, 2019-2026

Blood Screening Market Size, Share & Industry Analysis, By Product Type (Instruments, and Reagents & Kits), By Technology (Molecular Tests, and Serology Tests), By End User (Independent Clinical Laboratories, Hospital-based Laboratories, and Others), and Regional Forecast, 2019-2026

Contract Manufacturing Organization (CMO) Market Size, Share & Industry Analysis, By Type (API Manufacturing, Finished Dosage Form Manufacturing (Solid Dosage Forms, Injectables, and Others), and Packaging), and Regional Forecast, 2019-2026

Electronic Health Records (EHR) Market Size, Share & Industry Analysis, By Product (Web-based, On-premise), By Type (Stand Alone, Integrated) By End User (Physician's Office, Hospitals, Others) and Regional Forecast, 2019-2026

Blood Pressure Monitoring Market Size, Share and Industry Analysis By Product Type (Sphygmomanometers, Digital Blood Pressure Monitors, Ambulatory Blood Pressure Monitors), By End User (Hospitals, Ambulatory Surgery Centers & Clinics, Home Healthcare & Others), and Regional Forecast 2018-2025

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India.

Phone: US :+1 424 253 0390 UK : +44 2071 939123 APAC : +91 744 740 1245 Email: sales@fortunebusinessinsights.com Fortune Business Insights LinkedIn | Twitter | Blogs

Press Release: https://www.fortunebusinessinsights.com/press-release/biobanking-market-9759

View post:
Biobanking Market to Reach $49.46 Billion by 2026; Recent Breakthrough Concepts have Indicated Potential in Covid-19 Vaccine, says Fortune Business...

THAILAND’S EXCEPTIONAL STRENGTHS AS THE WORLD’S MEDICAL HUB – Bangkok Post

Thailands internationally-admired performance in the pandemic of the COVID-19 virus has showcased the exceptional strengths of the countrys health care system and medical industry to further justify its drive towards becoming one of the worlds top medical hubs.

A sophisticated healthcare system, universal healthcare coverage and robust public health consciousness have all contributed to Thailands success in containing the pandemic of COVID-19 virus and reporting one of the worlds lowest mortality rates from the disease.

Johns Hopkins Universitys 2019 Global Health Security Index1 ranked Thailand as the worlds 6th best prepared country for confronting the pandemic, reflecting the countrys public health care systems preparedness for coping with major public health emergencies such as the pandemic of the Covid-19 virus.

YouGov in partnership with the Institute of Global Health Innovation at Imperial College London released results from a survey2 in May which showed that Thais are the most likely to wear facemasks in public and use hand sanitizer as hygienic routines, across six countries in Association of Southeast Asian Nations (ASEAN).

This strong local medical environment, together with growing demand for health care locally and from abroad and the Thai governments commitment to further develop the medical industry have enabled Thailand to be the most lucrative market for medical device manufacturing in Asia.

Placing Thailands health care and wellness service and its comprehensive medical industry among 13 key industries that represent the countrys new engines of growth over the next decade in line with the Thailand 4.0 policy, the Thai government has established a plan to develop the countrys medical sector as the global Medical Hub. This policy is a national strategy aiming of creating sustainable human development through the leverage of Thailands strengths in the manufacturing supply chain, the medical industry and biotechnology to build economic competitiveness over the long-term.

This position is reiterated in the Ministry of Public Health 2016-2025 plan for Thailand to become the worlds foremost destination for medical industry in four key areas of wellness, medical services, academic activities and medical products.

Cost advantage, high-quality medical services, attentive care of medical staff and unique wellness services have spurred demand for Thailands medical and wellness from abroad. The Ministry of Tourism & Sports is promoting Thailands medical and wellness tourism at the global level.

Thailands large healthcare industry is currently supported by 370 private hospitals, 50 of which are accredited by the Joint Commission International (JCI) global standard, while there were also 18 JCI-accredited medical clinics as of September 2019. This number is greater than any other countries in ten- membered ASEAN and fourth highest in the world.

Thailands attractive overall investment climate is underlined by rising competitiveness in many areas. The World Bank ranks Thailand at the 21st place out of 190 economies on the 2020 Ease of Doing Business Index, reflecting the countrys conducive regulatory environment for starting and operation of local firms3.

The World Bank also ranks Thailand at the 32nd out of 160 countries on the Logistics Performance Index in 2018, second only to Singapore in ASEAN4 for the biennial study.

These positive factors and Thailands strategic location as the gateway to growing economies of Cambodia, Lao PDR, Myanmar, and Vietnam enable Thailand to offer an ideal investment destination for a wide range of medical device manufacturers and healthcare service providers.

Growing Prospects for Medical Devices

Thailands economic competitiveness, rising demand from aging population,expanding middle class and more tourists seeking affordable high-quality health care services have supported growing future prospect for medical device industry. On top of that, the pandemic of the COVID-19 virus adds an impetus to the demand for a wide range of medical devices from frontline medical practitioners to general populations and accelerates the medical systems adoption of more advanced medical devices.

Thailand boasts a strong industrial manufacturing supply chain and agricultural businesses to support the pharmaceuticals, medical food production and medical device manufacturing.

As a testament to the growing medical industry and importance of export base, Thailands outbound shipment of medical devices grew to US$ 843 million in 2018 from US$ 554 million in 2011. The value of imports grew to US$ 962 million from US$ 557 million, over the same period.

Electromechanical devices, in vitro diagnostic devices, single-use devices,ophthalmic devices, optical devices, and hospital hardware represented Thailands top medical device imports in 2018.

The reliance on the import of sophisticated medical devices underscores the significant potential for investment opportunities in Thailand. Thailand Board of Investment offers a wide range of incentives for investments that meet the national development objectives. The available tax incentives include the exemption of both corporate income tax and import duty on machinery and raw or essential materials used in manufacturing products for the export.

As for non-tax incentives, the BOI also grants the permission for foreign investors to hold up to 100 % ownership in most targeted businesses. Additionally, the BOI enhances the coverage and benefits of its Smart Visa program to attract the high-skilled experts, investors, and foreign start-ups in targeted high- technology industries under the Thailand 4.0 policy.

The BOI also introduces additional incentives to promote new investment by medical device manufacturers and industrial manufacturers who wish to adjust their production to meet the surge in the use of medical devices to cope with the epidemic of the Covid-19 virus.

Thriving Pharmaceutical Market

Thailands Universal Coverage Scheme, which now covers almost all of the countrys 70 million population, the rise in the medical demand from tourists and robust biotechnology have driven Thailand to be one of the strongest- performing pharmaceutical markets to support the medical care and wellness services in the Asia-Pacific region.

As Thailand becomes more integrated in ASEANs trade cooperation,the countrys market share for the export of pharmaceuticals to the Cambodia,Lao PDR, Myanmar and Vietnam and ASEAN countries continues to grow.

Foreign investment in Thailands pharmaceutical sector is also increasing,as the BOI is offering incentives to compensate overseas investors for increased burdens stemming from the upgrade of production facilities required to meet GMP standards (as per the PIC/S requirements). Such incentives include reducing operators costs and, as such, applicants for investment support who made successful applications in 2017-2018 are eligible for an 8-year corporate tax waiver.

The pharmaceuticals and medical device manufacturing sectors are also among the governments targeted industries. If such businesses are established in the Eastern Economic Corridor (EEC) special economic zone which spans Chachoengsao, Chonburi, and Rayong provinces in the countrys Eastern region, they are also eligible for further investment support in the form of financial assistance with research and additional tax waivers.

Leading in R&D

With robust medical systems and the high caliber of their medical researchers, several Thai agencies have established themselves as leaders in the field of research and development and clinical trials in ASEAN. Leading in the battle against Covid-19, Siam Bioscience Co., Ltd. under the collaboration with Thailands Department of Medical Science has produced the first Thai-made RT-PCR test kits for the COVID-19 virus. The test kits, which meet the World Health Organizations standard, were distributed to the medical laboratories across the country for speedy detection of the virus.

To facilitate more advanced biological products, Thailands government has put in place a complete regulatory framework to support local research and development activities such as derivations of blood, vaccine, proteins and Advanced Therapy Medical Products (ATMP) such as cell therapy products, gene therapy products and stem cell therapy products, including the Cell Therapy Act.

The strong governments support, high-quality medical system and lower cost attracts a large number of biotechnology companies and contract research organizations to Thailand to conduct clinical trials for cures in ongoing high prevalence diseases such as HIV/ AIDS, Hepatitis, heart disease, cancer, dengue, malaria and infectious diseases including various strains of flu.

Read the original:
THAILAND'S EXCEPTIONAL STRENGTHS AS THE WORLD'S MEDICAL HUB - Bangkok Post

Health News Roundup: Ahead of Trump rally in Oklahoma, coronavirus cases; Amazon forest fires could increase risk of COVID infections and more -…

Following is a summary of current health news briefs.

Ahead of Trump rally in Oklahoma, coronavirus cases surge in several states

Just days before U.S. President Donald Trump's campaign rally in Tulsa, the biggest event in the country since pandemic restrictions were imposed in March, new coronavirus cases are surging in Oklahoma, Arizona and other states. The spike in new cases reported on Wednesday and over the last two weeks points to a troubling trend in the United States, where cases have risen nationally after falling for more than a month.

Amazon forest fires could increase risk of serious coronavirus infections

An intense season of fires in the Amazon rainforest this year could overwhelm health systems and lead to unnecessary deaths, including of coronavirus, as pollution worsens respiratory conditions, public health experts said on Wednesday. Forest fires destroy many thousands of hectares of Amazon rainforest across Latin America each year. As peak burning season approaches, experts say intense fires and the particles they give off could exacerbate coronavirus infections.

EU calls for global alliance to buy COVID-19 vaccines up front

The European Commission called on Wednesday for global leaders to cooperate to buy bulk quantities of potential COVID-19 vaccines, to avoid "harmful competition" in the race for a shot and ensure any future vaccine is available for poor countries. With around a dozen potential vaccines now in human trials, rich countries have been rushing to buy up doses in advance from pharmaceutical companies, to make sure they will have enough supply should any prove successful.

Gilead to enroll pediatric patients for late-stage remdesivir study

Drugmaker Gilead Sciences said on Wednesday it will soon begin enrollment of pediatric patients with moderate-to-severe COVID-19 in a late-stage study testing its experimental drug, remdesivir. The trial will assess the effectiveness and safety of the drug in the patients, which would include newborns to adolescents, across more than 30 sites in the United States and Europe, the company said.

Steroid should be kept for serious coronavirus cases, WHO says

A cheap steroid that can help save the lives of patients with severe COVID-19 should be reserved for serious cases in which it has been shown to provide benefits, the World Health Organization said on Wednesday. WHO chief Tedros Adhanom Ghebreyesus said research was at last providing "green shoots of hope" in treating the virus, which has killed more than 400,000 people worldwide and infected more than 8 million.

'Medicaid best price' changes aimed at value-based gene therapy contracts: U.S. agency

Proposed changes to requirements that state-run Medicaid programs are given the best drug prices would clear the way for commercial health insurers to enter into "value-based" payment schemes, the U.S. Centers for Medicare & Medicaid Services said on Wednesday. Drug manufacturers by law must give Medicaid their "best price," meaning the lowest price they negotiate with any other buyer. But health plans have expressed concerns that the requirement prevents them from linking drug prices to patient outcomes - a practice known as "value-based" pricing.

Requiring masks 'political hazard' as COVID-19 surges in California breadbasket

The first wave of COVID-19 came slowly to San Joaquin County in the heart of California's breadbasket, but the much-feared second surge is roaring through, sickening as many people in the two weeks since Memorial Day as in March and April combined. Hospitalizations have spiked by 40%, and the county is one of ten in the most populous U.S. state put on a watch list of places that might be ordered to lock down their economies again after weeks of careful reopening.

Italian study shows no improvement from Roche's rheumatoid arthritis drug for COVID-19

Roche Holding AG's Actemra did not improve symptoms in patients with early-stage COVID-19 pneumonia, scientists conducting a study of the drug in Italy said on Wednesday, raising questions about the potential of the Swiss drugmakers' rheumatoid arthritis drug to treat the novel coronavirus. The study compared patients who received anti-inflammation drug Actemra to those given standard treatment, and concluded that Actemra did not reduce severe respiratory symptoms, intensive care visits, or death.

Black patients with COVID-19 in Atlanta more likely to be hospitalized: CDC

A study of coronavirus patients in Atlanta has found that black patients are more likely to be hospitalized than white patients, highlighting racial disparities in the U.S. healthcare system, researchers from the Centers for Disease Control and Prevention (CDC) said on Wednesday. About 79% of black patients were hospitalized for COVID-19, the disease caused by the novel coronavirus, against 13% of white patients, according to the study https://www.cdc.gov/mmwr/volumes/69/wr/mm6925e1.htm?s_cid=mm6925e1_w across six metropolitan hospitals and outpatient clinics in Atlanta, Georgia, between March and April 2020.

WHO sees 'green shoots' of hope in COVID-19 pandemic

Signs of hope are starting to show in the fight against the COVID-19 pandemic, the World Health Organization (WHO) said on Wednesday, but it added that countries must continue to work on prevention measures to limit the spread of the new coronavirus. While cases are "still rapidly rising" in many regions of the world, there are "green shoots of hope", the WHO's Director General Tedros Adhanom Ghebreyesus said in an online media briefing.

See more here:
Health News Roundup: Ahead of Trump rally in Oklahoma, coronavirus cases; Amazon forest fires could increase risk of COVID infections and more -...

Stem Cell Therapy Market Analysis On Trends & Need 2025 3w Market News Reports – 3rd Watch News

Global Stem Cell Therapy Market: Overview

Also called regenerative medicine, stem cell therapy encourages the reparative response of damaged, diseased, or dysfunctional tissue via the use of stem cells and their derivatives. Replacing the practice of organ transplantations, stem cell therapies have eliminated the dependence on availability of donors. Bone marrow transplant is perhaps the most commonly employed stem cell therapy.

Osteoarthritis, cerebral palsy, heart failure, multiple sclerosis and even hearing loss could be treated using stem cell therapies. Doctors have successfully performed stem cell transplants that significantly aid patients fight cancers such as leukemia and other blood-related diseases.

Know the Growth Opportunities in Emerging Markets

Global Stem Cell Therapy Market: Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

The regional analysis covers:

Order this Report TOC for Detailed Statistics

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Continue reading here:
Stem Cell Therapy Market Analysis On Trends & Need 2025 3w Market News Reports - 3rd Watch News

2025 Projeaction: Cancer Stem Cell Market 2020 Industry Research, Segmentation, Key Players Analysis and Forecast to 2025 – Cole of Duty

This report additionally covers the effect of COVID-19 on the worldwide market. The pandemic brought about by Coronavirus (COVID-19) has influenced each part of life all inclusive, including the business segment. This has brought along a several changes in economic situations.

A report on Cancer Stem Cell market compiled by Brand Essence Market Research provides a succinct analysis regarding the values and trends existing in the current business scenario. The study also offers a brief summary of market valuation, market size, regional outlook and profit estimations of the industry. Furthermore, the report examines the competitive sphere and growth strategies of leading players in the Cancer Stem Cell market. Download Premium Sample of the Report: https://industrystatsreport.com/Request/Sample?ResearchPostId=476&RequestType=Sample

TheMajorPlayersCovered in this Report:Thermo Fisher Scientific, Inc., AbbVie, Inc., Merck KGaA, Bionomics, LONZA, Stemline Therapeutics, Inc, Miltenyi Biotec, PromoCell GmbH, MacroGenics, Inc., ONCOMED PHARMACEUTICALS INC, Irvine Scientific, STEMCELL Technologies Inc, Sino Biological Inc, BIOTIME, INC., Others & More.

Reports include the following segmentation: By Type:Treatment Typeo Autologous Stem Cell Transplantso Allogeneic Stem Cell Transplantso Syngeneic Stem Cell Transplantso Bone Marrow Stem Cell TransplantsDisease Typeo Breast Cancero Blood Cancero Lung Cancero Brain Cancero Colorectal Cancero Pancreatic Cancero Bladder Cancero Liver Cancero OthersBy End-Use:Hospitals and Surgical CentresPharmaceutical and Biotech CompaniesCell Banks and Tissue BanksAcademic Institutes, Research Laboratories, and CROsOthersBy RegionNorth Americao U.S.o Canadao MexicoEuropeo UKo Franceo Germanyo Russiao Rest of EuropeAsia-Pacifico Chinao South Koreao Indiao Japano Rest of Asia-PacificLAMEAo Latin Americao Middle Easto Africa

Results of the recent scientific undertakings towards the development of new Cancer Stem Cell products have been studied. Nevertheless, the factors affecting the leading industry players to adopt synthetic sourcing of the market products have also been studied in this statistical surveying report. The conclusions provided in this report are of great value for the leading industry players. Every organization partaking in the global production of the Cancer Stem Cell market products have been mentioned in this report, in order to study the insights on cost-effective manufacturing methods, competitive landscape, and new avenues for applications.

Global Cancer Stem CellMarket: Regional Segmentation For further clarification, analysts have also segmented the market on the basis of geography. This type of segmentation allows the readers to understand the volatile political scenario in varying geographies and their impact on the global Cancer Stem Cellmarket. On the basis of geography, the global market for Cancer Stem Cellhas been segmented into:

North America(United States, Canada, and Mexico) Europe(Germany, France, UK, Russia, and Italy) Asia-Pacific(China, Japan, Korea, India, and Southeast Asia) South America(Brazil, Argentina, Colombia, etc.) Middle East and Africa(Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Grab Your Report at an Impressive Discount @ https://industrystatsreport.com/Request/Sample?ResearchPostId=476&RequestType=Methodology

Report Methodology:

The information enclosed in this report is based upon both primary and secondary research methodologies.

Primary research methodology includes the interaction with service providers, suppliers, and industry professionals. Secondary research methodology includes a meticulous search of pertinent publications like company annual reports, financial reports, and exclusive databases.

Table of Content:

Market Overview: The report begins with this section where product overview and highlights of product and application segments of the Global Cancer Stem Cell Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company: Here, the competition in the Worldwide Global Cancer Stem Cell Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data: As the name suggests, this section gives the sales data of key players of the Global Cancer Stem Cell Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the Global Cancer Stem Cell Market.

Market Status and Outlook by Region: In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the Global Cancer Stem Cell Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User: This section of the research study shows how different end-user/application segments contribute to the Global Cancer Stem Cell Market.

Market Forecast: Here, the report offers a complete forecast of the Global Cancer Stem Cell Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion: This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Top Trending Reports:

https://www.marketwatch.com/press-release/global-armored-vehicles-market-size-share-application-analysis-regional-outlook-growth-trends-key-players-and-competitive-strategies-forecast-to-2025-2020-06-17?tesla=y

https://www.marketwatch.com/press-release/europe-microcontroller-market-size-share-growth-companies-industry-report-2020-2025-2020-06-17?tesla=y

https://www.marketwatch.com/press-release/chromatography-resin-market-2020-market-2020-by-key-features-advancements-companies-profile-industry-verticals-development-rapid-growth-and-business-strategy-2025-2020-06-09

https://www.marketwatch.com/press-release/at-cagr-of-33-bio-plasticizers-market-2020-size-sharetypes-applications-forecast-and-covid-19-impact-analysis-2025-2020-06-09

Read the original here:
2025 Projeaction: Cancer Stem Cell Market 2020 Industry Research, Segmentation, Key Players Analysis and Forecast to 2025 - Cole of Duty

15 Biotech Companies In Houston To Know – Built In

Houston has played a significant role in boosting the nations biotech industry. While Houston is still a hotspot for energy and oil, the city is steadily becoming a burgeoning life sciences hub. In fact, the city boasted the third fastest-growing biotech community in the nation between 2014 and 2017, according to a CBRE report. Houstons biotech industry is gaining momentum due to an increase in funding as well. According to the Greater Houston Partnership, nearly $180 million in VC funding was allocated to the citys ecosystem of life sciences-related companies in 2019 alone.

Like many startups and tech companies across Houston, the citys life sciences leaders have been tackling some of the worlds most pressing issues. Whether theyre developing oncology drug candidates or advancing genomic medicine through the creation of sequencing technologies, the citys biotech organizations are pulling on decades of research and determination to transform the medical landscape on a global scale. Heres a look at 15 biotech companies in Houston making a major impact on medical research and discovery.

Founded: 2015

Focus: Canine Cancer Treatment

What they do:CAVU Biotherapiesprovides immune-based solutions to treat cancer and autoimmune diseases in dogs. The company offers an immune health monitoring service, which describes a dogs immune system through the use of a blood sample, as well as an autologous prescription product that retrains and expands a dogs T cells to recognize and fight cancer. CAVU Biotherapies ultimate aim is to use its immune-guided medicine to treat horses, cats, andeventually, humans.

Founded: 2006

Focus: Stem Cell Banking + Therapy

What they do: Founded by David Eller and Dr. Stanley Jones, Celltex Therapeutics focuses on developing stem cell therapies for a variety of conditions. The companys stem cell processing and banking methods are designed to ensure the genetic integrity and uniformity of an individuals cells in quantities necessary for therapeutic applications. Using proprietary technology, Celltex Therapeutics enables stem cells to be used for regenerative therapy for conditions like vascular, autoimmune and degenerative diseases.

Founded: 2006

Focus: Cell Therapy

What they do: InGeneron is a clinical stage cell therapy company that specializes in novel, evidence-based regenerative medicine therapies. The companys therapy is designed to repair injured tissue, improve the quality of life for patients and modify the progression of their disease. InGeneron focuses mainly on musculoskeletal indications such as pain management.

Founded: 2006

Focus: Cancer Treatment

What they do: Moleculin Biotech is a pharmaceutical company dedicated to the treatment of highly resistant cancers and viruses. The company develops oncology drug candidates for highly resistant tumors as well as as prodrug to exploit the potential uses of inhibitors of glycolysis. Guided by the aim to provide new hope to cancer patients, Moleculin Biotech focuses on discovering new treatments for acute myeloid leukemia, skin cancer, pancreatic cancer and brain tumors.

Founded: 2001

Focus: Nanomedicine

What they do: Nanospectra Biosciences is spearheading a patient-centric use of nanomedicine for the removal of cancerous tissues. The companys ultra-focal nanoshell technology is designed to thermally destroy solid tumors without damaging adjacent healthy tissue. Nanospectra Biosciences aims to maximize treatment efficacy while minimizing side effects associated with surgery, radiation and traditional focal therapies.

Founded: 2018

Focus: Cell Therapy

What they do: Marker Therapeutics is an immuno-oncology company that focuses on the development of next-generation T cell-based immunotherapies. With the aim of treating hematological malignancies and solid tumor indications, the company uses its own MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells. Marker Therapeutics is also working on developing proprietary DNA expression technology that is intended to improve the cellular immune systems ability to recognize and destroy diseased cells.

Founded: 2008

Focus: 3D Cell Culture

What they do: Nano3D Biosciences is dedicated to the development of 3D cell culture solutions. The companys core technology allows them to levitate or bioprint cells, which results in the formation of cultures that are more easily assembled and handled. Nano3D Biosciences products and services are intended for biomedical research, drug discovery, precision medicine, toxicology and regenerative medicine.

Founded: 2017

Focus: Small Molecule Inhibitors

What they do: Tvardi Therapeutics is a clinical-stage biotech company working on a new class of medicines for cancer, chronic inflammation and fibrosis. The company is focusing on the creation of orally delivered, small molecule inhibitors of STAT3, which is a key regulatory protein positioned at the intersection of many disease pathways. Tvardi Therapeutics is dedicated to delivering safe and effective solutions for use in the treatment of numerous diseases.

Founded: 2011

Focus: Targeted Cancer Therapies

What they do: Salarius Pharmaceuticals focuses on developing targeted therapies to treat various types of cancers. The companys lead candidate, Seclidemstat, is intended to treat Ewing sarcoma, a pediatric and young adult bone cancer that currently lacks targeted therapies. Salarius Pharmaceuticals performs clinical trials for the treatment of other advanced solid tumors including prostate, breast and ovarian cancers.

Founded: 2013

Focus: Genomic Medicine

What they do: Founded by Michael Metzker, RedVault Biosciences develops technologies with the aim of advancing genomic medicine. The company is currently working on a variety of projects including the development of sequencing technologies to determine haplotypes and structural variation in complex genomes. RedVault Biosciences is dedicated to identifying technology needs, creating and testing ideas, and transferring deliverables to production and distribution.

Founded: 2010

Focus: DNA Sequencing

What they do: Avance Biosciences focuses on assay development, assay validation and sample testing using next-generation DNA sequencing and other biological methods. The company offers biologics testing, diagnostic assay validation, GMO genomic testing, gene / cell therapy testing, digital and real-time PCR, microbial testing and more. Avance Biosciences aim is to assist its clients in advancing drug development and genomic research.

Founded: 2008

Focus: Bioremediation

What they do: Bionex Technology develops cost-effective, natural solutions for cleaning oil-polluted soil. The companys Super Microbe spill solution is naturally derived from microbes that digest and convert harmful contaminants on the ground and in soil, therefore lowering flammability, suppressing harmful vapors and creating a safer environment for spill responders. Bionex Technology offers a variety of other bioremediation products such as a customizable degreaser and detergent used for cleaning industrial tools.

Founded: 2016

Focus: Stem Cell Research

What they do: Located in nearby Sugar Land, Hope Biosciences is dedicated to developing stem cell-based therapies that are safe, effective and secure. The companys proprietary technology enables patients to make virtually unlimited and identical stem cells from their own tissue. Hope Biosciences offers stem cell banking solutions for both adults and newborns.

Founded: 2013

Focus: Interventional Cardiology

What they do: Saranas has created technology that enables the early detection and monitoring of bleeding complications associated with vascular access procedures. The companys monitoring system checks changes in the blood vessels electrical resistance before monitoring if bleeding has occurred from an unintentionally injured blood vessel. Saranas aims to allow physicians to mitigate downstream consequences by addressing bleeds before they become complications.

Founded: 1984

Focus: Microbiology

What they do: Microbiology Specialists Inc. specializes in microbiology testing, playing a role in microbial investigations and studies. The company also focuses on infectious disease diagnosis, forensic bacteriology and mycology, medical device testing and infection prevention. Microbiology Specialists Inc. is committed to delivering reliable, accurate and cost-effective microbiological results.

Read the original:
15 Biotech Companies In Houston To Know - Built In

Stem Cell Banking Market Overview and Regional Outlook with Research Study 2019 2026 – Cole of Duty

The global Stem Cell Banking Market size will rise at a considerable rate in the coming years. Driven by recent advancements in the material associated with manufacturing of the product, the market will rise at a rapid pace. According to a report by Fortune Business Insights, titled Global Stem Cell Banking Market Is Expected to Reach Around USD 13.36 Billion By 2025, the market will derive growth from recent product advancements.

Stem Cell Banking Market report provides a thoroughly researched abstract of the key players with considerable shareholdings at a global level regarding demand, sales, and income by providing better products and services. Research Report outlines a forecast for theStem Cell Banking Marketbetween 2020 and 2027. In terms of value, the Stem Cell Banking Market is expected to register a steady CAGR during the forecast period.

Get Sample PDF [emailprotected]https://www.zionmarketresearch.com/requestbrochure/stem-cell-banking-market

The research report provides a big picture on Stem Cell Banking Market 2027, on a global basis, offering a forecast and statistic in terms of revenue during the forecast period. This report covers detailed segmentation, complete R & D history, and explanatory analysis including the latest news. Furthermore, the study explains the future opportunities and a sketch of key players involved in theStem Cell Banking Marketin terms of revenue.

The Leading Market Players Covered in this Report are:

Cord Blood Registry (CBR) Systems, Cordlife Group Limited, Cryo-Cell International, ViaCord, Cryo-Save, LifeCell International, StemCyte, Global Cord Blood Corporation, Vita34, Smart Cells International, and CryoHoldco

This Research Help Grow Your Business [Download Sample PDF Of Research Report]

The scope of the Report:

The research report on global Stem Cell Banking Market includes segmentation on the basis of technology, application, end users, and region. Each segmentation is a chapter, which explains relevant components. The chapters include graphs to explain the year-on-year progress and the segment-specific drivers and restraints. In addition, the report also provides the government outlooks within the regional markets that are impacting the global Stem Cell Banking Market.

Global Stem Cell Banking Market: Segment Analysis

The globalStem Cell Banking Marketis segmented on the basis of technology, products, services, and applications. The segmentation is intended to give the readers a detailed understanding of the global market and the essential factors comprising it. This allows giving a better description of the drivers, restraints, threats, and opportunities. It also notes down socio-economic factors that are impacting the trajectory of the globalStem Cell Banking Market.

Inquire More about Report:https://www.zionmarketresearch.com/inquiry/stem-cell-banking-market

Global Stem Cell Banking Market: Regional Analysis Different regions of the global market influence growth differently. Various factors such as economic growth, technological developments, government policies, availability of labor, and others are compared with each to determine which region will outperform other. The regions included in this report are North America, Europe, Asia Pacific, and the Middle East and Africa.

Global Stem Cell Banking Market: Competitive Landscape

Competitive landscape of a report determines the overall scenario of the market focusing on key players and their strategic moves. Readers can get an insight of how various key players are performing in the market and the scope for emerging players.

Strategic Points Covered in TOC:

Chapter 1:Introduction, market driving force product scope, market risk, market overview, and market opportunities of the globalStem Cell Banking Market Chapter 2:Evaluating the leading manufacturers of the globalStem Cell Banking Marketwhich consists of its revenue, sales, and price of the products

Chapter 3:Displaying the competitive nature among key manufacturers, with market share, revenue, and sales

Chapter 4:Presenting globalStem Cell Banking Marketby regions, market share and with revenue and sales for the projected period

Chapter 5, 6, 7, 8 and 9:To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions

Browse Full Report:https://www.zionmarketresearch.com/report/stem-cell-banking-market

Else place an Inquire before Purchase Global Stem Cell Banking Market Size, Status and Forecast 2027:

Worldwide Stem Cell Banking Market Report Provides Comprehensive Analysis of:

The classification of the global Stem Cell Banking Market is done based on the product type, segments, and end-users. The report provides an analysis of each segment together with the prediction of their development in the upcoming period. Additionally, the latest research report studies various segments of the global Stem Cell Banking Market in the anticipated period.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

(*If you have any special requirements, please let us know and we will offer you the report as you want.)

Continue reading here:
Stem Cell Banking Market Overview and Regional Outlook with Research Study 2019 2026 - Cole of Duty